|
|
???tair.name??? >
???browser.page.title.author???
|
"hsu kuo hsuan"???jsp.browse.items-by-author.description???
Showing items 1-10 of 64 (7 Page(s) Totally)
1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-06T02:04:30Z |
Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
|
Liao, Pei-Ya; Ou, Wei-Fan; Su, Kang-Yi; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-09-06T02:02:15Z |
Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
|
Wu, Jia-Jun; Lee, Po-Hsin; Zheng, Zhe-Rong; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU; Chen, Kun-Chieh; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-09-06T01:59:43Z |
Various impacts of driver mutations on the PD-L1 expression of NSCLC
|
Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; Su, Kang-Yi; SUNG-LIANG YU; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-09-06T01:55:22Z |
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
|
Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Su, Kang-Yi; SUNG-LIANG YU; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-06-14T23:24:02Z |
Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR‐Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
|
Liao, Pei Ya; Ou, Wei Fan; KANG-YI SU; Sun, Ming Hsi; Huang, Chih Mei; Chen, Kun Chieh; Hsu, Kuo Hsuan; SUNG-LIANG YU; Huang, Yen Hsiang; Tseng, Jeng Sen; Yang, Tsung Ying; Chang, Gee Chen |
| 臺大學術典藏 |
2022-05-14T23:35:34Z |
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
|
Huang, Yen Hsiang; Hsu, Kuo Hsuan; Tseng, Jeng Sen; Yang, Tsung Ying; Chen, Kun Chieh; KANG-YI SU; SUNG-LIANG YU; Chen, Jeremy J.W.; Chang, Gee Chen |
| 臺大學術典藏 |
2022-05-14T23:35:34Z |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
|
Huang, Yen Hsiang; Hsu, Kuo Hsuan; Chin, Chun Shih; Tseng, Jeng Sen; Yang, Tsung Ying; Chen, Kun Chieh; KANG-YI SU; SUNG-LIANG YU; Chen, Jeremy J.W.; Chang, Gee Chen |
| 臺大學術典藏 |
2022-05-12T06:47:07Z |
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
|
Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Su, Kang-Yi; SUNG-LIANG YU; Chen, Jeremy J W; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-05-12T06:43:52Z |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
|
Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Su, Kang-Yi; SUNG-LIANG YU; Chen, Jeremy J W; Chang, Gee-Chen |
| 臺大學術典藏 |
2022-05-12T06:04:19Z |
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
|
Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU; Yu, Sung-Liang; Chen, Jeremy J W; Chang, Gee-Chen |
Showing items 1-10 of 64 (7 Page(s) Totally)
1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
|
